{
    "N/R/U": null,
    "Applicant": "Pfizer Inc.",
    "BLA Number": "125786",
    "Proprietary Name": "BEQVEZ",
    "Proper Name": "fidanacogene elaparvovec-dzkt",
    "BLA Type": "351(a)",
    "Strength": "1x E13 VG/ML",
    "Dosage Form": "Suspension",
    "Route of Administration": "Intravenous",
    "Product Presentation": "Single-Dose Vial",
    "Marketing Status": "Rx",
    "Licensure": "Licensed",
    "Approval Date": "April 25, 2024",
    "Ref. Product Proper Name": null,
    "Ref. Product Proprietary Name": null,
    "Supplement Number": "0",
    "Submission Type": "Original",
    "License Number": "2001",
    "Product Number": "001",
    "Center": "CBER",
    "Date of First Licensure": "April 25, 2024",
    "Exclusivity Expiration Date": null,
    "First Interchangeable Exclusivity Exp. Date": null,
    "Ref. Product Exclusivity Exp. Date": "April 25, 2036",
    "Orphan Exclusivity Exp. Date": "April 25, 2031"
}